References

Influence of nomenclature changes on trends in papillary thyroid cancer incidence in the United States, 2000 to 2017.

10.1210/clinem/dgaa690 · 2020 · External reference

Differentiated thyroid cancer: management of patients with radioiodine nonresponsive disease.

10.1155/2012/618985 · 2012 · External reference

Natural history and clinical outcome of differentiated thyroid carcinoma: a retrospective analysis of 1503 patients treated at a single institution.

10.1093/annonc/mdp050 · 2009 · External reference

2025 American Thyroid Association management guidelines for adult patients with differentiated thyroid cancer.

10.1177/10507256251363120 · 2025 · External reference

Radiofrequency ablation and thyroid cancer: review of the current literature.

10.1016/j.amjoto.2021.103204 · 2022 · External reference

Approach to and treatment of differentiated thyroid carcinoma.

10.1016/j.mcna.2012.01.002 · 2012 · External reference

Progress in molecular-based management of differentiated thyroid cancer.

10.1016/s0140-6736(13)60109-9 · 2013 · External reference

Radioactive iodine-refractory differentiated thyroid cancer: an uncommon but challenging situation.

10.1590/2359-3997000000245 · 2017 · External reference

Nivolumab versus everolimus in advanced renal-cell carcinoma.

10.1056/nejmoa1510665 · 2015 · External reference

Nivolumab for recurrent squamous-cell carcinoma of the head and neck.

10.1056/nejmoa1602252 · 2016 · External reference

Head and Neck cancers—major changes in the American Joint Committee on Cancer eighth edition cancer staging manual.

10.3322/caac.21389 · 2017 · External reference

A prospective, multi-institutional, pathologist-based assessment of 4 immunohistochemistry assays for PD-L1 expression in non-small cell lung cancer.

10.1001/jamaoncol.2017.0013 · 2017 · External reference

“Interchangeability” of PD-L1 immunohistochemistry assays: a meta-analysis of diagnostic accuracy.

10.1038/s41379-019-0327-4 · 2020 · External reference

Development of an automated PD-L1 immunohistochemistry (IHC) assay for non-small cell lung cancer.

10.1097/pai.0000000000000256 · 2015 · External reference

Development of a prototype immunohistochemistry assay to measure programmed death ligand-1 expression in tumor tissue.

10.5858/arpa.2015-0544-oa · 2016 · External reference

Sensitive detection of BRAF V600E mutation by amplification refractory mutation system (ARMS)-PCR.

10.1186/2050-7771-1-3 · 2013 · External reference

Programmed death-ligand 1 expression in papillary thyroid cancer and its correlation with clinicopathologic factors and recurrence.

10.1089/thy.2016.0228 · 2017 · External reference

Serum levels of soluble programmed death ligand 1 predict treatment response and progression free survival in multiple myeloma.

10.18632/oncotarget.5682 · 2015 · External reference

High level of soluble programmed cell death ligand 1 in blood impacts overall survival in aggressive diffuse large B-Cell lymphoma: results from a French multicenter clinical trial.

10.1038/leu.2014.137 · 2014 · External reference

Programmed death-ligand 1 overexpression is a prognostic marker for aggressive papillary thyroid cancer and its variants.

10.18632/oncotarget.8698 · 2016 · External reference

Clinical significance of soluble programmed cell death ligand-1 (sPD-L1) in hepatocellular carcinoma patients treated with radiotherapy.

10.1016/j.radonc.2017.11.027 · 2018 · External reference

Elevated levels of soluble PD-L1 are associated with reduced recurrence in papillary thyroid cancer.

10.1530/ec-19-0210 · 2019 · External reference

PD-L1 expression and its modulating factors in anaplastic thyroid carcinoma: a multi-institutional study.

10.1097/pas.0000000000002284 · 2024 · External reference

Programmed death-ligand 1 (PD-L1) is a potential biomarker of disease-free survival in papillary thyroid carcinoma: a systematic review and meta-analysis of PD-L1 immunoexpression in follicular epithelial derived thyroid carcinoma.

10.1007/s12022-020-09630-5 · 2020 · External reference

PD-L1 and PD-1 expression are correlated with distinctive clinicopathological features in papillary thyroid carcinoma.

10.1186/s13000-017-0662-z · 2017 · External reference

Combined expression of the BRAFV600E mutation and PD-L1 in early papillary thyroid carcinoma and its relationship with clinicopathological features and recurrence-a retrospective cohort study.

10.21037/gs-22-701 · 2022 · External reference